No Clinically Significant Drug-Drug Interaction Between Allopurinol and Letrozole
There is no documented drug-drug interaction between allopurinol and letrozole, and these medications can be safely co-administered without dose adjustments.
Evidence Review
FDA Drug Label Information
The FDA-approved letrozole drug label explicitly addresses drug interactions and states that clinical experience shows no significant interactions with cimetidine or warfarin 1. Importantly, the label makes no mention of allopurinol as an interacting drug 1.
Similarly, the allopurinol FDA label lists specific drugs requiring dose adjustments or monitoring, including mercaptopurine, azathioprine, dicumarol, thiazide diuretics, chlorpropamide, cyclosporine, ampicillin/amoxicillin, and cyclophosphamide 2. Letrozole is not mentioned among these interactions.
Mechanism Considerations
These drugs operate through completely different metabolic pathways:
- Allopurinol inhibits xanthine oxidase and is metabolized to oxypurinol, with renal elimination 3
- Letrozole is an aromatase inhibitor with no involvement in purine metabolism 4
The only documented interaction with letrozole involves tamoxifen, which reduces letrozole plasma levels by approximately 38% through enzyme induction 5. This mechanism is unrelated to allopurinol's pharmacology.
Clinical Context
Patients with breast cancer receiving letrozole may develop hyperuricemia requiring allopurinol, particularly if they have concurrent gout or are receiving chemotherapy that increases uric acid levels 6. The absence of any reported interaction in clinical guidelines for breast cancer management 7, 8, 9 or gout management 10 supports the safety of concurrent use.
Practical Recommendations
You can prescribe these medications together without concern for drug-drug interactions. However, monitor each drug independently for its own adverse effects:
- For allopurinol: Monitor for hypersensitivity reactions (especially in patients with renal impairment), adjust dose for kidney function, and check uric acid levels 10
- For letrozole: Monitor for musculoskeletal symptoms, bone density changes, and cardiovascular effects 8
The only caveat is if the patient is also taking azathioprine or mercaptopurine, which would require a 65-75% dose reduction when combined with allopurinol 6, 2.